Vaccines
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
mRNA has built its reputation as a type of vaccine to fight COVID-19, but its capabilities extend beyond vaccines into therapeutics and even diagnostics.
Moderna is expected to launch a human clinical trial as early as this week for an mRNA-based vaccine against HIV and indicated that it is looking for 56 people ages 18 to 50 who are HIV-negative.
This approval makes TICOVAC the only FDA-backed vaccine in the U.S. to protect people of all ages against the virus when visiting or living in TBE endemic regions.
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
Women who are pregnant are more vulnerable to developing severe illness after infection with SARS-Cov-2, the novel coronavirus that causes COVID-19.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
PRESS RELEASES